Core Insights - Niagen Bioscience has partnered with OneSpaWorld to offer Niagen IV at over 80 Medi-Spa clinics on high-end cruise ships, marking its first cruise ship clinic partnership [1][2] - This collaboration aims to expand Niagen Plus' presence and provide premium wellness experiences to vacationing consumers [2][3] Company Overview - Niagen Bioscience, Inc. is a leader in NAD+ science and healthy aging research, focusing on innovative NAD+-boosting solutions [6][9] - The company has developed a next-generation intravenous formulation of pharmaceutical-grade Niagen, designed to enhance cellular vitality and support healthy aging [3][9] Product Details - Niagen IV is a 500 mg intravenous solution that offers a better patient experience with 75% shorter infusion times and a quicker rise in NAD+ blood levels compared to traditional NAD+ IV [3][5] - The product is compounded and distributed by FDA-registered outsourcing facilities, ensuring high safety and quality standards [9][5] Market Expansion - The partnership with OneSpaWorld opens a new premium channel for Niagen IV, enhancing the company's clinical footprint, which already includes over 1,200 wellness clinics across the U.S. [2][5] - OneSpaWorld operates health and wellness services on 208 cruise ships, providing a significant opportunity for Niagen Bioscience to reach new consumers [10][5] Strategic Goals - The collaboration supports Niagen Bioscience's strategy to scale its offerings outside the U.S. and tap into the growing demand for wellness services among travelers [2][3] - The company continues to broaden its intellectual property portfolio, recently securing a patent for the methods of use of Niagen in IV and injectable formulations [3][10]

Core Viewpoint - Niagen Bioscience, Inc. will participate in the 38th Annual ROTH Conference, focusing on healthy aging and NAD+ science, with key presentations and meetings scheduled for March 22-24, 2026 [1][2]. Company Overview - Niagen Bioscience, Inc. is recognized as the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy aging research, dedicated to advancing healthspan through innovative NAD+-boosting solutions [4][5]. - The company’s product portfolio includes Niagen®, a patented nicotinamide riboside (NR), which is the most efficient and well-researched NAD+ booster available [7]. Conference Participation - CEO Rob Fried will participate in the Technologies Advancing Healthy Aging Panel on March 23, 2026, at 2:00 PM PT, which will be livestreamed [2][4]. - The conference will feature one-on-one and small-group meetings, analyst-selected fireside chats, and industry keynotes, with participation from executive management of numerous companies [3]. Research and Development - Niagen Bioscience has established over 300 external research agreements with global institutions, contributing to 45 published clinical studies, marking a significant milestone in NAD+ research support [12]. - The company collaborates with renowned scientists and research institutions to explore the potential of NAD+, which is crucial for cellular function and declines with age [5][6]. Financial Performance - In fiscal year 2025, Niagen Bioscience reported a 30% year-over-year increase in net sales, reaching $129.4 million, and a 103% increase in net income to $17.4 million [14]. - The fourth quarter of 2025 saw total net sales increase by 16% to $33.8 million, with Tru Niagen® sales rising by 21% to $27.5 million [15].

Corporate Presentation Nasdaq: NAGE | March 2026 Safe Harbor Statement This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements reflect the current view about future events. Statements that are not historical in nature, such as 2025 financial ...

Core Insights - Niagen Bioscience has announced the sale of its ChromaDex Reference Standards business to LGC in an all-cash transaction, aimed at streamlining operations and focusing on core activities related to NAD+ science and healthy aging [1] Company Strategy - The divestiture is part of Niagen Bioscience's strategy to exit non-core activities and allocate resources towards NAD+ science, intellectual property, and commercial growth within the longevity industry [1] - CEO Rob Fried emphasized that this transaction allows the company to focus on advancing NAD+ science and delivering patented Niagen® solutions [1] Acquisition Details - The sale to LGC is expected to enhance LGC's capabilities in supporting pharmaceutical customers, testing laboratories, and food producers by expanding their reference materials and analytical standards portfolio [1] - LGC Standards, a division of LGC Group, is recognized as a global leader in life sciences and analytical solutions [1] Market Position - Niagen Bioscience is positioned as a leader in NAD+ science and healthy aging research, with a focus on innovative NAD+-boosting solutions [1] - The company’s flagship product, Niagen®, is noted as the most efficient and well-researched NAD+ booster available [1] Future Outlook - Niagen Bioscience is dedicated to advancing healthspan through precision science and innovative solutions, with a robust patent portfolio protecting its NAD+ precursors [1]

Financial Performance - Total company net sales reached $34 million in Q3 2025, a 33% increase year-over-year[10] - Tru Niagen® net sales were $26 million in Q3 2025, up 44% year-over-year[10] - Gross margin improved to 64.5% in Q3 2025, a 100 basis points increase year-over-year[10] - Net income was $4.6 million, or $0.06 earnings per share, an increase of $2.7 million and $0.04 year-over-year[10] - Adjusted EBITDA reached $6.4 million, up $3.5 million year-over-year[10] - Cash provided from operations year-to-date was $12.8 million, with $64.3 million in cash and no debt[10] Sales Mix and Growth - Tru Niagen® net sales accounted for 77% of total net sales in Q3 2025, compared to 71% in Q3 2024[28] - Niagen®-related net sales remained at 97% of total net sales in both Q3 2025 and Q3 2024[28] - Year-to-date net sales reached $99.6 million, a 36% increase year-over-year[34] Outlook - The company reaffirmed its increased full-year 2025 net sales growth outlook to between 25% and 30%, driven by strong momentum in Tru Niagen® and Niagen® ingredients[10]

Financial Performance - Q2 2025 - Total company net sales reached $31.1 million, a 37% year-over-year increase[10] - Tru Niagen® net sales were $22.7 million, representing a 22% year-over-year increase[10] - Niagen® ingredient sales surged to $7.4 million, marking a 135% year-over-year increase[10] - Gross margin improved to 65.0%, up 480 basis points year-over-year[10] - Net income was $3.6 million, or $0.05 earnings per share, a $3.6 million year-over-year increase[10] - Adjusted EBITDA reached $5.0 million, a $3.5 million year-over-year increase[10] Financial Position - Cash provided from operations year-to-date was $9.1 million, with a cash balance of $60.5 million and no debt[10] Sales Mix - Q2 2025 - E-commerce accounted for 57% of net sales, while Watson's & Other B2B represented 25%[26] - Food-grade Niagen® contributed 14% to net sales, and Analytical Reference Standards & Services accounted for 3%[26] - Other Ingredients made up 1% of net sales[26] 2025 Outlook - The company anticipates net sales growth between 22% and 27% year-over-year[10] - Sales and marketing expenses are expected to increase in absolute dollars but decrease as a percentage of net sales year-over-year[10]

Financial Highlights - ChromaDex's total net sales reached $83.5 million in 2023, with Tru Niagen® sales contributing $69.5 million[14] - Tru Niagen® sales experienced a 52% Compound Annual Growth Rate (CAGR)[11] - E-commerce net sales reached $51.2 million in 2023, demonstrating an 85% CAGR[16] - Gross margin increased from 49.4% to 60.8% following a strategic shift towards Tru Niagen®[17] - ChromaDex reported a positive Adjusted EBITDA of $1.9 million in 2023[11, 12] Market and Product - ChromaDex identifies as the global authority on NAD+ with a Total Addressable Market (TAM) exceeding $500 billion across human and pet nutrition, cosmetics, and pharmaceuticals[11] - Tru Niagen® is identified as a proprietary NAD+ boosting supplement[11] - Approximately 60% of ChromaDex's business is attributed to e-commerce[15] - North America accounts for 75% of Tru Niagen® net sales, followed by APAC with 22%[56] Research and Development - ChromaDex has invested in over $100 million of third-party research supporting the benefits of its proprietary ingredient[11] - ChromaDex holds a strong intellectual property portfolio, including over 80 patents for Niagen® and other NAD+ precursors[11]

Company Overview - ChromaDex is a global authority on NAD+ with a strong intellectual property portfolio for Niagen® and other NAD precursors[8] - The company has strategic partnerships with blue chip companies and a strong financial position, with $4 million LTM Adjusted EBITDA and $28 million in cash as of June 30, 2024[8] - ChromaDex's LTM revenue ended June 2024 was $856 million, with a net loss of $14 million and non-GAAP Adjusted EBITDA of $4 million[25] Consumer Health (Tru Niagen®) - Tru Niagen® has proven to be a proprietary NAD+ boosting supplement with LTM sales of over $80 million[8] - E-commerce represents approximately 60% of the Tru Niagen® business[34] - Annual e-commerce net sales have grown at a CAGR of 85% from 2017 to 2023[35], reaching $512 million in 2023[35] - Gross margin increased from 494% to 608% since the strategic pivot to focus on the consumer product, Tru Niagen®[36] IV & Injectables (Niagen®+) - The company estimates the incumbent NAD+ IV retail market in North America is worth at least $100 million[49] - Niagen®+ IV offers competitive advantages over NAD+ IV, including 75% faster infusion time and minimal side effects[50] Pharmaceutical - ChromaDex is pioneering the development of Parkinson's Disease treatment, with a Phase III study underway involving 400 participants supplemented with NR for 12 months at a 1000mg daily dose, with results expected in 2025[59, 60] Financial Outlook - The company projects net sales growth between 10%-15% year-over-year for 2024[69]

Financial Performance - Q1 2025 - Total company net sales reached $30.5 million, a 38% increase year-over-year (YoY)[10] - Tru Niagen® net sales were $21.5 million, up 24% YoY[10] - Niagen® ingredient sales increased significantly to $8.0 million, a 95% YoY increase[10] - Gross margin improved to 63.4%, a 270 basis points increase YoY[10] - Net income was $5.1 million, or $0.07 earnings per share, an increase of $5.6 million and $0.08 YoY[10] - Adjusted EBITDA was $4.9 million, up $4.2 million YoY[10] - The company ended the quarter with $55.6 million in cash and no debt, with cash provided from operations at $7.9 million year-to-date[10] Sales Mix - Q1 2025 - E-commerce accounted for 58% of net sales in Q1 2025, compared to 55% in Q1 2024[26] - Watson's & Other B2B represented 20% of net sales in Q1 2025, up from 16% in Q1 2024[26] - Food-grade Niagen® contributed 19% of net sales in Q1 2025, down from 23% in Q1 2024[26] - Tru Niagen® net sales accounted for 71% of total net sales in Q1 2025, compared to 78% in Q1 2024[27] - Niagen®-related net sales remained at 97% of total net sales in both Q1 2025 and Q1 2024[27] Financial Outlook - 2025 - The company adjusted its full-year 2025 net sales growth outlook to between 20%-25%, previously approximately 18%[10] - Adjusted general and administrative expenses outlook was revised upwards by $7.0 to $8.0 million, previously $5.0 to $6.0 million[10]

Financial Performance - Q4 2024 - Total company net sales reached $29.1 million, a 37% year-over-year increase[11] - Tru Niagen® net sales amounted to $22.7 million, representing a 29% year-over-year growth[11] - Niagen® ingredient sales experienced substantial growth, reaching $5.3 million, a 96% year-over-year increase[11] - Gross margin improved to 62.5%, a 150 basis points increase compared to the previous year[11] - Net income significantly increased to $7.2 million, a $7.1 million increase year-over-year[11] - Adjusted EBITDA nearly tripled, reaching $3.4 million compared to $1.2 million in Q4 2023[11] Financial Performance - Full Year 2024 - Total net sales grew by 19% year-over-year[11] - Net income reached $8.6 million, or $0.11 earnings per share, compared to a net loss of $4.9 million, or $0.07 loss per share in the previous year[11] - Operating cash flows amounted to $12.1 million, with a year-end cash balance of $44.7 million and no debt[11] - Adjusted EBITDA increased to $8.5 million, up from $1.9 million in FY 2023[11] 2025 Outlook - The company anticipates continued revenue growth of approximately 18% year-over-year[11]